Cardiovascular Drugs and Therapy

, Volume 24, Issue 2, pp 131–137

Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure

  • Yuliy Y. Chirkov
  • Michele De Sciscio
  • Aaron L. Sverdlov
  • Sue Leslie
  • Peter R. Sage
  • John D. Horowitz
Article

Abstract

Purpose

The A-HeFT trial demonstrated incremental survival with hydralazine/isosorbide dinitrate combination in African–American patients with chronic heart failure (CHF). It has been suggested that hydralazine might enhance nitric oxide (NO)—mediated effects of organic nitrates by decreasing superoxide (O2) formation, one of the factors inducing NO resistance. We evaluated whether hydralazine therapy potentiates nitrate-induced vasodilation and inhibition of platelet aggregation by ameliorating NO resistance.

Methods

Patients (n = 14) with NYHA class II-III CHF were studied in a randomised, double-blind, placebo-controlled, crossover study of the effects of hydralazine therapy (25 mg b.d., for 1 week) on physiological responsiveness to glyceryl trinitrate (GTN). Vascular response to GTN was assessed via applanation tonometry, as change in augmentation index (AIx) over time. Platelet responsiveness to GTN and sodium nitroprusside (SNP) was determined, as inhibition of ADP-induced platelet aggregation. O2 release was evaluated during aggregation via lucigenin-derived chemiluminescence.

Results

Platelet responsiveness to the NO donors GTN and SNP was impaired, denoting the presence of severe NO resistance. Hydralazine therapy decreased systolic blood pressure by 6.8 ± 10.5 (S.D.) mmHg (p = 0.02), and caused a reduction in AIx by 15 ± 24% (p = 0.03). However, there were no significant changes in platelet aggregability and associated O2 release, or in platelet or vascular responses to NO donor.

Conclusion

The results of the present study do not support the assumption that hydralazine could be viewed as a “NO enhancer”; there is no evidence of attenuation of NO resistance by hydralazine treatment.

Key words

Chronic heart failure Glyceryl trinitrate Hydralazine Nitric oxide Platelet aggregation Superoxide Vasodilatation 

References

  1. 1.
    Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the African American Heart Failure Trial. Am J Cardiol. 2005;96:37i–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Horowitz JD. Nitrovasodilators. In: Loscalzo J, Vita JA, editors. Nitric oxide and the cardiovascular system. Totowa: Humana; 2000. p. 383–410.CrossRefGoogle Scholar
  3. 3.
    Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther. 2007;116:287–305.CrossRefPubMedGoogle Scholar
  4. 4.
    Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Hare JM. Nitroso-redox balance in the cardiovascular system. (Editorial). N Engl J Med. 2004;351:2112–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Franciosa JA. Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opin Pharmacother. 2006;7:2521–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitrate tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest. 1996;98:1465–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Bassenge E, Sommer O, Schwemmer M, Bünger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am J Physiol Heart Circ Physiol. 2000;279:H2431–8.PubMedGoogle Scholar
  10. 10.
    Vidrio H, González-Romo P, Alvarez E, Alcaide C, Orallo F. Hydralazine decreases sodium nitroprusside-induced rat aortic ring relaxation and increased cGMP production by rat aortic myocytes. Life Sci. 2005;77:3105–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Horowitz JD. Is there a pharmacological hydralazine/nitrate interaction in chronic heart failure? (abstract). Eur Heart J. 2008;29:300 [P1956].Google Scholar
  12. 12.
    Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation. 1999;100:129–34.PubMedGoogle Scholar
  13. 13.
    Raitakari OT, Seale JP, Celermajer DS. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am J Cardiol. 2001;87:217–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest. 2006;116:2330–2.PubMedGoogle Scholar
  15. 15.
    Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Sage PR, Horowitz JD. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Anderson RA, Ellis GR, Chirkov YY, et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail. 2004;6:47–54.CrossRefPubMedGoogle Scholar
  17. 17.
    Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol. 2004;93:1438–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Ellis GR, Anderson RA, Chirkov YY, et al. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial dysfunction in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001;37:564–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol. 1998;32:S33–7.PubMedGoogle Scholar
  20. 20.
    Liberts EA, Willoughby SR, Kennedy JA, Horowitz JD. Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris. Eur J Pharmacol. 2007;560:49–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Harker LA, Zimmerman TS, editors. Measurements of platelet function. New York: Churchill Livingstone; 1983. p. 64–91.Google Scholar
  22. 22.
    Madsen NJ, Holmes CE, Serrano FA, Sobel BE, Schneider DJ. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Am J Cardiol. 2007;100:722–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Daiber A, Mülsch A, Hink U, Warnholtz A, Oelze M, Münzel T. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol. 2005;96:25i–36.CrossRefPubMedGoogle Scholar
  24. 24.
    Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to haemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Elkayam U, Karaalp IS, Wani OR, Tummala P, Akhter MW. The role of organic nitrates in the treatment of heart failure. Prog Cardiovasc Dis. 1999;4:255–64.CrossRefGoogle Scholar
  26. 26.
    Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G. Hydralazine prevents endothelial dysfunction, but not the increase in superoxide production in nitric oxide-deficient hypertension. Eur J Pharmacol. 1998;362:77–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Salvemini D, de Nucci G, Sneddon JM, Vane JR. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol. 1989;97:1145–50.PubMedGoogle Scholar
  28. 28.
    Tam SW, Sabolinski ML, Worcel M, Packer M. Cohn JN Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. Clin Pharmacokinet. 2007;46:885–95.CrossRefPubMedGoogle Scholar
  29. 29.
    Flack JM. Editorial commentary on: Franciosa JA “Fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opin Pharmacother. 2006;8:275–7.CrossRefGoogle Scholar
  30. 30.
    Ellison GT, Kaufman JS, Head RF, Martin PA, Kahn JD. Flaws in the U.S. Food and Drug Administration’s rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients. J Law Med Ethics. 2008;36:449–57.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Yuliy Y. Chirkov
    • 1
  • Michele De Sciscio
    • 1
  • Aaron L. Sverdlov
    • 1
  • Sue Leslie
    • 1
  • Peter R. Sage
    • 1
  • John D. Horowitz
    • 2
    • 1
  1. 1.Cardiology Unit, Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, School of Medicine, The University of AdelaideAdelaideAustralia
  2. 2.Cardiology Unit, The Queen Elizabeth HospitalAdelaideAustralia

Personalised recommendations